SCHEMBL3023137

SCHEMBL3023137

O=S(=O)(c1ccccc1Br)N1CCN(c2nc(-c3ccc(Cl)c(Cl)c3)cs2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.56
SMN1; SMN2 Q16637 5/20 0.56
MEN1 O00255 2/20 0.56
LMNA P02545 2/20 0.56
KMT2A Q03164 2/20 0.56
ALDH1A1 P00352 2/20 0.56
AR P10275 2/20 0.56
MAPK1 P28482 3/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
USP2 O75604 2/20 0.46
HSD17B10 Q99714 2/20 0.46
RECQL P46063 1/20 0.46
GBA1 P04062 2/20 0.45
TSHR P16473 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
RAB9A P51151 1/20 0.42
ABL1 P00519 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013278 0.91 KMT2A (0.59) MAPTSMN1; SMN2MEN1LMNAKMT2A
SCHEMBL3002592 0.91 SMN1; SMN2 (0.59) MAPTSMN1; SMN2MEN1LMNAKMT2A
SCHEMBL3015400 0.91 AR (0.60) MAPTSMN1; SMN2MEN1LMNAKMT2A
SCHEMBL3012669 0.90 MAPT (0.61) MAPTSMN1; SMN2MEN1LMNAKMT2A
SCHEMBL3013262 0.89 SMN1; SMN2 (0.55) MAPTSMN1; SMN2MEN1LMNAKMT2A
SCHEMBL3019990 0.87 LMNA (0.67) MAPTSMN1; SMN2MEN1LMNAKMT2A
SCHEMBL3003033 0.87 SMN1; SMN2 (0.56) MAPTSMN1; SMN2MEN1LMNAKMT2A
SCHEMBL3014682 0.87 KMT2A (0.61) MAPTSMN1; SMN2MEN1LMNAKMT2A
SCHEMBL3018650 0.87 LMNA (0.57) MAPTSMN1; SMN2MEN1LMNAKMT2A
SCHEMBL3014513 0.87 MAPT (0.57) MAPTSMN1; SMN2MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885SMN1; SMN2 1/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.